A new start-up has risen from the ashes of the closure of Pfizer Inc.’s research facility in Sandwich, U.K. announced in February 2011. On Nov. 5, Ziarco said it raised the first $6 million tranche of a $27 million Series A round.
Ziarco Picks Up Pfizer Assets, Series A Round
A former Pfizer VP used four of the pharma’s programs to secure private financing from an unlikely investor and got the pharma to buy into the new start-up. Now, he hopes to develop next generation treatments for inflammatory and allergic diseases.